Discounted Cash Flow (DCF) Analysis Levered

Corbus Pharmaceuticals Holdings, In... (CRBP)

$ 0.8173
-0.00 (-0.33%)
Stock DCF: -1,339.50 | 0.8173 | overvalue

Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 1.912.444.8236.143.9410.6929.0178.73213.68579.99
Revenue (%)
Operating Cash Flow -13.57-27.80-30.07-45.72-99.69-109.67-297.66-807.90-2,192.83-5,951.81
Operating Cash Flow (%)
Capital Expenditure -0.35-0.71-2.30-2.74-0.48-2.46-6.67-18.12-49.17-133.46
Capital Expenditure (%)
Free Cash Flow -13.92-28.50-32.37-48.46-100.17-112.12-304.33-826.02-2,242-6,085.28

Weighted Average Cost Of Capital

Share price $ 0.8,173
Beta 1.845
Diluted Shares Outstanding 81.88
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 10.206
Total Debt 19.74
Total Equity 66.92
Total Capital 86.66
Debt Weighting 22.78
Equity Weighting 77.22
Wacc

Build Up Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 1.912.444.8236.143.9410.6929.0178.73213.68579.99
Operating Cash Flow -13.57-27.80-30.07-45.72-99.69-109.67-297.66-807.90-2,192.83-5,951.81
Capital Expenditure -0.35-0.71-2.30-2.74-0.48-2.46-6.67-18.12-49.17-133.46
Free Cash Flow -13.92-28.50-32.37-48.46-100.17-112.12-304.33-826.02-2,242-6,085.28
WACC
PV LFCF -102.85-256.05-637.49-1,587.12-3,951.39
SUM PV LFCF -6,534.90

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 9.02
Free cash flow (t + 1) -6,389.54
Terminal Value -158,943.78
Present Value of Terminal Value -103,207.83

Intrinsic Value

Enterprise Value -109,742.73
Net Debt -65.69
Equity Value -109,677.04
Shares Outstanding 81.88
Equity Value Per Share -1,339.50